Pharma & Biotech Updates
Pfizer and BioNTech (BNTX) received a positive CHMP opinion for their LP.8.1‑adapted COVID‑19 vaccine, reinforcing momentum in the pandemic response.
Gilead (GILD) secured an accelerated CHMP opinion for its twice‑yearly Lenacapavir, strengthening its leadership in innovative HIV prevention therapies.
Bristol Myers Squibb (LLY) earned a favorable CHMP opinion for its Alzheimer’s treatment Donanemab while completing its acquisition of Verve Therapeutics to advance one‑time treatments for high‑risk cardiovascular patients.
ImmunityBio (IBRX) reported a 60% revenue increase in Q2 2025, with year‑to‑date sales reaching $43 million, boosted by an $80 million equity financing round.
Sarepta Therapeutics (SRPT) faced a CHMP negative opinion for ELEVIDYS in the European Union, a setback that could trigger a review of its regulatory strategy.
Moderna (MRNA) received a positive opinion from the EMA for its updated COVID‑19 mRNA vaccine targeting the SARS‑CoV‑2 variant LP.8.1, showcasing its agile response to viral evolution.
Krystal Biotech (KRYS) announced the approval of its VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for treating dystrophic epidermolysis bullosa, marking a key regulatory win.
Inmagene Biopharmaceuticals (IMA) completed its merger with Ikena Oncology, coupled with a concurrent private placement of $75 million, strategically bolstering its therapeutic pipeline.
Recognify Life Sciences (ATAI) provided an update on its Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia, underscoring ongoing R&D efforts.
Celcuity (CELC) is set to announce topline results for the PIK3CA wild‑type cohort from its Phase 3 VIKTORIA‑1 trial in HR+/HER2‑ advanced breast cancer, a critical milestone in its clinical program.
Portage Biotech (PRTG) reported its fiscal year results for the period ending March 31, 2025, offering key insights into its performance in a competitive biotech landscape.
Tech & Mobility Developments
Pony.ai (PONY) launched 24/7 robotaxi services in major Chinese cities, driving forward autonomous mobility solutions with expanded operational hours.
XPeng (XPEV) initiated its global localization strategy in Indonesia with a locally‑produced X9 delivery model, broadening its international footprint.
Vonage (ERIC) earned dual recognition from Gartner®, being named both a Customers' Choice and a Visionary, a testament to its competitive edge in communications technology.
Earnings & Financial Highlights
CenterPoint Energy (CNP) committed to $53 billion in long‑term investments, signaling robust confidence in the energy sector’s growth prospects.
Centene Corporation (CNC) unveiled its Q2 2025 results, providing key insights into its competitive positioning within the healthcare market.
AST SpaceMobile (ASTS) priced a private offering of $500 million in convertible senior notes due 2032, underlining its strategic capital initiatives.
Moog Inc. (MOG) posted record third quarter 2025 results, with standout sales and earnings per share underpinning its market leadership.
Charter Communications (CHTR) reported strong Q2 2025 outcomes, reinforcing its continued dominance in the communications sector.
HCA Healthcare (HCA) delivered solid Q2 2025 earnings, demonstrating resilience in a transforming healthcare landscape.
Volcon (VLCN) initiated a strategic Bitcoin treasury program and expanded its share repurchase authorization to $100 million, reflecting an innovative approach to financial strategy. Read the full report.
Galaxy (GLXY) executed one of the largest notional Bitcoin transactions ever, a move that exemplifies the growing interplay between crypto dynamics and financial markets.
Energy & Resources
Fusion Fuel (HTOO) unveiled new LPG projects for its subsidiary, Al Shola Gas, reaffirming its commitment to expanding clean energy solutions.
ASP Isotopes Inc. (ASPI) had its offer for Renergen Limited approved by South Africa’s Competition Commission, a regulatory milestone poised to reshape market dynamics.
TotalEnergies (TTE) published its financial report for the first half of 2025, offering investors critical insights into its performance and strategic direction.
